

Form PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>		ATTY. DOCKET NO.	SERIAL NO.
		078728-0106	09/833,745
		APPLICANT	
		Joseph ROBERTS et al.	
FILING DATE 04/13/2001		GROUP ART UNIT <i>1652</i> <i>Unassigned</i>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	A1	Joseph Roberts et al., "Biologic and Antineoplastic Effects of Enzyme-Medicated In Vivo Depletion of L-L Glutamine, L-Tryptophan, and L-Histidine", Cancer Treatment Reports Vol. 63, No. 6, 6/79, pps. 1045-1054.	
	A2	Holcnenberg et al., "Enzymes As Drugs", Ann. Rev. Pharmacol., Toxicol, 1977 17:97-116, Copyright 1977 by Annual Reviews Inc.	
	A3	Shibatani, et al., "Cyrtallin L-Histidine Ammonia-Lyase of Achromobacter liquidum Crystallization and Enzymic Properties, Bur J. Biochem, 5, 263-269 (1975)	
	A4	Wu et al., "Histidine ammonia-lyase from Streptomyces griseus", 1992 Elsevier Science Publishers B.V. 0378- 4119/92, pgs. 19-25. <i>Gene 115, 19-25</i>	
	A5	Jack et al., "The Effect of Histidine Ammonia-Lyase On Some Murine Tumours", Leukemia Research Vol., No. 3, pp. 421-429, 1983.	
	A6	Khanna et al., "Characterization of L-histidine ammonia-lyase immobilized by microencapsulation in artificial Cells: preparation, kinetics, stability and in vitro depletion of histidine", The International Journal of Artificial Organs, Vol. 13, No. 3, 1990, pp. 189-195.	
	A7	Consevage et al., "Sequence Analysis of the <i>hutH</i> Gene Encoding Histidine Ammonia-Lyase in Pseudomonas Putida", Journal of Bacteriology, May 1990, pp. 2224-2229. <i>177</i>	
	A8	Oda et al., "Cloning and Nucleotide Sequences of histidase and Regulatory Genes in the <i>Bacillus subtilis hut</i> Operon and Positive Regulation of the Operon", Journal of Bacteriology, July 1988, pp. 3199-3205. <i>178</i>	
	A9	Wu et al., "Purification of Histidase from Streptomyces griseus and Nucleotide Sequence of the <i>hutH</i> Structural Gene", Journal of Bacteriology, March 1992, pp. 1647-1655. <i>179</i>	
	A10	Taylor et al., "Cloning and Expression of Rat Histidase", The Journal of Biological Chemistry, Vol. 265, No. 30 October 25, pp. 18192-18199, 1990.	
	A11	Okamura et al., "L-Histidine Ammonia-lyase in Rat Liver, J. Biochem, 75, 139-152, 1974.	
	A12	Watanabe et al., "Induction of Histidine Decarboxylase Activity In Mouse Skin After Application of Indole Alkaloids, A New Class of Tumor Promoter", Biochemical and Biophysical Research Communications, Vol. 109, No. 2, 1982, pp. 478-485.	
	A13	Bartholeyns et al., "Involvement of Histamine in Growth of Mouse and Rat Tumors: Antitumoral Properties of Monofluoromethylhistidine, and Enzyme-activated Irreversible Inhibitor of Histidine Decarboxylase", Cancer Research 44, 639-645, February 1984.	
EXAMINER 		DATE CONSIDERED <i>10/31/02</i>	
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.			

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078728-0106	SERIAL NO. 09/833,745
INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>		APPLICANT	Joseph ROBERTS et al.	
		FILING DATE	04/13/2001	
		GROUP ART UNIT <i>1652</i> Unassigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
<i>CH</i>	A14	Hakii et al., "Thapsigargin, a histamine secretagogue, is a non-12-O-testradecanoylphorbol-13-acetate (TPA) Type tumor promoter in two-stage mouse skin carcinogenesis", Cancer Research Clinical Oncology, 1986, <i>III</i> , <i>pp. 111-116. pp. 177-180</i>		
	<i>CH</i>	A15	Mitra et al., "Histamine and Cis-Urocanic Acid Augment Tumor Necrosis Factor-Alpha Mediated Induction of Keratinocyte Intercellular Adhesion Molecule-1 Expression", Journal of Cellular Physiology 156:348-357, 1993	
<i>CH</i>		A16	Wiley-Liss, Inc. Stolfi et al., "Chemotherapeutic Activity of L-Histidinol against Spontaneous, Autochthonous Murine Breast Tumors", Chemotherapy 1990, 36:435-440.	
	<i>CH</i>	A17	Warrington et al., "L-Histidinol Reverses Resistance to Cisplatin and Other Antineoplastics in a Tumorigenic Epithelial Cell Line, Anticancer Research 16:3641-3646, 1996.	
<i>CH</i>		A18	Warrington et al., "Reversal of the Multidrug-Resistant Phenotype of Chinese Hamster Ovary Cells by L-Histidinol", Journal of the National Cancer Institute 89:803. <i>(1989)</i>	
	<i>CH</i>	A19	Warrington et al., "Improved Treatment of Disseminated B16f10 Melanoma in Mice with Anticancer Drugs in Combination with L-Histidinol", Anticancer Research 11:1869-1874, 1991.	
<i>CH</i>		A20	Warrington et al., "Susceptibility of Human Colon Carcinoma Cells to Anticancer Drugs Is Enhanced by L-Histidinol", Anticancer Research 14:367-372, 1994.	
	<i>CH</i>	A21	Warrington et al., "L-Histidinol Increases the Vulnerability of Cultured Human Leukemia and Lymphoma Cells to Anticancer Drugs", Anticancer Research 13:2107-2112, 1993.	
<i>CH</i>		A22	Warrington et al., "L-Histidinol in experimental cancer chemotherapy: improving the selectivity and efficacy of Anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype", Biochem, Cell Biol., Vol. 70, 365-375, 1992.	
	<i>CH</i>	A23	Zaharko et al., "L-Histidinol: Preclinical Therapeutic Studies in Combination with Antitumor Agents and Pharmacokinetic Studies in Mice", Cancer Research 52, 3604-3609, July 1992.	
<i>CH</i>		A24	Warrington et al., "L-Histidinol Selectively Modulates Daunomycin Toxicity in Normal and Tumorigenic Kidney Epithelial Cells", Anticancer Research 16:3629-3634, 1996.	
	<i>CH</i>	A25	Badary et al., "Effect of L-Histidinol on Cisplatin Nephrotoxicity in the Rat", Karger AG, Basel 0028- 2766/07/0774-0435. <i>NEPTON (1997) 77, 435-439</i>	
<i>CH</i>		A26	Al-Shababah et al., "Effects of L-Histidinol On The Antitumour Activity and Acute Cardiotoxicity of Doxorubicin In Mice", Pharmacological Research, Vol. 38, No. 3, 1998, Article Number 2980355. <i>225-230</i>	
	EXAMINER <i>CH</i>	DATE CONSIDERED <i>10/31/02</i>		
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.				

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078728-0106	SERIAL NO. 09/833,745
INFORMATION DISCLOSURE CITATION AUG 09 2001 (Use several sheets if necessary)		APPLICANT Joseph ROBERTS et al.	
		FILING DATE 04/13/2001	GROUP ART UNIT 1652 Unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CJY	A27	Badary, "L-Histidinol Attenuates Fanconi Syndrome Induced by Ifosfamide in Rats", Karger AG, Basel, 1018- 7782/99/0074, 323-327. <i>1990 EXP. NEPHROL 2, 725-327.</i>	
		Zaharko et al., "L-Histidinol: Preclinical Therapeutic Studies in Combination with Antitumor Agents and Pharmacokinetic Studies in Mice", Cancer Research 52, 3604-3609, July 1, 1992.	
CJY	A29	U.S. Department of Health and Human Services, "Hypothermia-Related Deaths, Virginia, November 1996- April 1997, December 12, 1997, Vol. 46, No. 49, pp. 1162-1165.	
		Noonan et al., "Immunosuppression by ultraviolet B radiation: initiation by urocanic acid", Immunology Today, Vol. 13, No. 7, 1992, pp. 250-254.	
CJY	A31	Altschul et al., "Gapped BLAST and PSA-BLAST: a new generation of protein database search programs", Nucleic Acids Research, Vol. 25, No. 17, 1997, pp. 3389-3402.	
		Gish et al., "Identification of protein coding regions by database similarity search", Nature Genetics, Vol. 3, 1993, pp. 266-272.	
CJY	A33	Madden et al., "[9] Applications of Network BLAST Server", Methods in Enzymology, Vol. 266, pp. 131-141.	
		Altschul et al., "Basic Local Alignment Search Tool", J. Mol. Biol. Vol. 215, 1990, pp. 403-410.	
CJY	A35	Zhang et al., "PowerBLAST: A New Network BLAST Application for Interactive or Automated Sequence Analysis and Annotation", Genome Research, Vol. 7, 1997, pp. 649-656.	
		Newman et al., "Selective Killing of Transformed Cells by Methotrexate with Histidine Deprivation or with Amino Alcohols", Cancer Research Vol. 43, October 1983, pp. 4703-4708.	
CJY	A37	Pardee et al., "Animal Cell Cycle", Ann. Rev. Biochem, Vol. 47, 1978, pp. 715-50.	
		Pardee, "A Restriction Point for Control of Normal Animal Cell Proliferation", Proc. Nat. Acad. Sci., Vol 71, No. 4, 1974, pp. 1286-1290	
CJY	A39	Warrington, "A Novel Approach for Improving the Efficacy of Experimental Cancer Chemotherapy Using Combinations of Anticancer Drugs and L-Histidinol", Anticancer Research, Vol. 6, 1986, 451-464.	
		Warrington, "L-Histidinol in experimental cancer chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype", Biochem. Cell Biol. Vol. 1992, pp. 365-375.	
CJY	A41	Hanson et al., "Epidermal trans-urocanic acid and the UV-A-induced photoaging of the skin", Proc. Natl. Acad. Sci., Vol. 95, 1998, pp. 10576-10578.	
		Norval, et al., "The Role of Urocanic Acid In Un-Induced Immunosuppression: Recent Advances (1992-1994), Photochemistry and Photobiology, Vol. 62, No. 2, 1995, pp. 209-217.	

EXAMINER

CJY

DATE CONSIDERED

10/31/02

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078728-0106	SERIAL NO. 09/833,745
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		O I P E AUG 0 9 2001 P R I M A T E S T A T E M A N T O F F I C E 181		APPLICANT Joseph ROBERTS et al.	
				FILING DATE 04/13/2001	GROUP ART UNIT 52 Unassigned
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)					
	A43	Kripke, "Ultraviolet Radiation and Immunology: Something New Under the Sun-Presidential Address", Cancer Research, Vol. 54, 1994, pp. 6102-6105.			
	A44	Logan et al., "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci., Vol. 81, June 1994, pp. 3655-3659.			
	A45	Rosenberg et al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression", Science, Vol. 242, December 16, 1988, pp. 1575-2578.			
	A46	Wolff et al., "Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease", Proc. Natl. Acad. Sci., Vol. 86, November 1989, pp. 9011-9014.			
	A47	Hodgson, "The Vector Void in Gene Therapy", Bio/Technology Vol. 13, March 1995, pp. 222-225.			
	A48	Caplen et al., "Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis", Nature Medicine, Vol. 1, Number 1, 1995, pp. 39-46.			
	A49	Zhu et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice", Science, Vol. 261, July 9, 1993, pp. 209-211.			
	A50	Berkner, "Development of Adenovirus Vectors for the Expression of Heterologous Genes", BioTechniques, Vol. 6, No. 7, 1988, pp. 616-626.			
	A51	Trapnell, "Adenoviral vectors for gene transfer", Advanced Drug Delivery Reviews, Vol. 12, 1993, pp. 185-199.			
	A52	Monks, "Feasibility of a High-Flux Anticancer drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines", Journal of the National Cancer Institute, Vol. 83, No. 11, June 5, 1991, pp. 757-766.			
EXAMINER <i>CP Waller</i>		DATE CONSIDERED <i>10/31/02</i>			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.					

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/833,745
Date Submitted: May 10, 2002				Filing Date	04/13/2001
(use as many sheets as necessary)				First Named Inventor	Joseph ROBERTS
				Group Art Unit	1645 (653)
				Examiner Name	Unassigned (RELENGER)
Sheet	1	of	1	Attorney Docket Number	078728-0106

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>CH</i>	B1	DE FABO et al. "Altered skin cytokine environment after UVB irradiation in UCA-deficient Histidinemic C57BL/6-HaLEdi mice," <u>Photochemistry and Photobiology</u> , Vol. 69, 06/1999, pp. 18S-19S, 27th Annual Meeting of the American Society of Photobiology, Washington, DC.	
<i>CH</i>	B2	BRAND et al. "Histidine ammonia-lyase from rat liver. Purification properties, and inhibition by Substrate analogues," <u>Biochemistry</u> , Vol. 15, No. 9, 1976, pp. 1814-1821.	TECH CENTER 1600/2900
			MAY 13 2002
			RECEIVED

MAY 13 2002

卷之三

Examiner Signature		Date Considered	04/02
-----------------------	---	--------------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

Language Translation is available.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.